These changes may return to normal after a longer period of follow-up.S9.3.1-16 Recommendation-Specific Supportive Text 1. Although treatment targets for hypertension after trans- plantation should probably be similar to those for other patients with CKD, there are no trials in post-transplan- tation patients comparing different BP targets. As kidney transplant recipients generally have a single functioning kidney and CKD, BP targets should be similar to those for the general CKD population. 2. Limited studies have compared drug choice for initial antihypertensive therapy in patients after kidney trans- plantation. On the basis of a Cochrane analysis,S9.3.1-2 most studies favor CCBs to reduce graft loss and main- tain higher GFR, with some evidence suggesting poten- tial harm from ACE inhibitors because of anemia, hyper- kalemia, and lower GFR. In recognition of this concern, RAS inhibitors may be reserved for the subset of patients with hypertension and additional comorbidities that sup- port the need for ACE inhibitor therapy (ie, proteinuria or HF after transplantation). With appropriate potassium and creatinine monitoring, this has been demonstrated to 9.4. Cerebrovascular Disease Stroke is a leading cause of death, disability, and dementia.S9.4-1 Because of its heterogeneous causes and hemodynamic con- sequences, the management of BP in adults with stroke is complex and challenging.S9.4-2 To accommodate the variety of important issues pertaining to BP management in the stroke patient, treatment recommendations require recognition of stroke acuity, stroke type, and therapeutic objectives. Future studies should target more narrowly defined questions, such as optimal BP-reduction timing and target, as well as ideal antihypertensive agent therapeutic class by patient type and event type. 9.4.1. Acute Intracerebral Hemorrhage Recommendations for Management of Hypertension in Patients With Acute Intracerebral Hemorrhage (ICH) References that support recommendations are summarized in Online Data Supplement 41. COR LOE Recommendations IIa C-EO 1. 